Successful treatment of psoriasis with risankizumab in an HIV positive patient with sexually transmitted infection comorbidities
2022
Abstrakt
The management of psoriasis in HIV-positive patients is challenging, particularly as data onbiologic therapy safety and efficacy in HIV-positive patients are limited. Risankizumab is a humanized IgG1 monoclonal antibody targeting the p19 subunit of interleukin-23 (IL-23) approved to treat psoriasis.
Risankizumab was generally well tolerated in clinical trials and found to be relatively safe. Thus, it could be a suitable treatment for patients with chronic infections such as HIV.